Cargando…

Efficacy and Safety of Topical Mechanistic Target of Rapamycin Inhibitors for Facial Angiofibromas in Patients with Tuberous Sclerosis Complex: A Systematic Review and Network Meta-Analysis

Previous studies have suggested that the topical mechanistic target of rapamycin (mTOR) inhibitors may be effective in treating facial angiofibromas in patients with tuberous sclerosis complex (TSC). Various concentrations of topical sirolimus for TSC have been tested, but their comparative efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lin, Yu-Ting, Yu, Chia-Ling, Tu, Yu-Kang, Chi, Ching-Chi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Systematic Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9025300/ https://www.ncbi.nlm.nih.gov/pubmed/35453576 http://dx.doi.org/10.3390/biomedicines10040826

Ejemplares similares

Topical rapamycin for facial angiofibromas in tuberous sclerosis complex
por: Safa, Gilles
Publicado: (2017)

Topical rapamycin (sirolimus) for facial angiofibromas
por: Madke, Bhushan
Publicado: (2013)

Efficacy and Safety of Topical Timolol for the Treatment of Facial Angiofibroma in Children with Tuberous Sclerosis Complex
por: Ghazavi, Mohammadreza, et al.
Publicado: (2023)

Facial Angiofibromas of Tuberous Sclerosis Treated with Topical Sirolimus in an Indian Patient
por: Vasani, Resham J
Publicado: (2015)

Facial Angiofibromas and Periungual Fibromas in Tuberous Sclerosis
por: Tsujimoto, Hiraku, et al.
Publicado: (2017)

Topical Rapamycin for Facial Angiofibromas in a Child with Tuberous Sclerosis Complex (TSC): A Case Report and Long-Term Follow-up
por: Ebrahimi-Fakhari, Daniel, et al.
Publicado: (2017)

Use of Topical Rapamycin in Facial Angiofibromas in Indian Skin Type
por: Viswanath, Vishalakshi, et al.
Publicado: (2016)

Sirolimus Ointment for Facial Angiofibromas in Individuals with Tuberous Sclerosis Complex
por: Amin, S., et al.
Publicado: (2017)

Isolated Unilateral Facial Angiofibroma or Segmental Tuberous Sclerosis Complex?
por: Supekar, Bhagyashree B., et al.
Publicado: (2021)

Improved health-related quality of life in patients treated with topical sirolimus for facial angiofibroma associated with tuberous sclerosis complex
por: Hatano, Takashi, et al.
Publicado: (2020)

Long-Term Exposure and Safety of a Novel Topical Rapamycin Cream for the Treatment of Facial Angiofibromas in Tuberous Sclerosis Complex: Results From a Single-Center, Open-Label Trial
por: Wheless, Margaret C., et al.
Publicado: (2019)

Impact of facial angiofibromas in tuberous sclerosis complex and reported efficacy of available treatments
por: Monaghan, Marie, et al.
Publicado: (2022)

Managing Different Spectrums of Tuberous Sclerosis Facial Angiofibroma: A Report of Two Cases
por: Mustaqim, Khairul, et al.
Publicado: (2023)

Dermoscopy of facial angiofibromas in Fitzpatrick II‐III phototype subjects affected by tuberous sclerosis complex
por: Lacarrubba, Francesco, et al.
Publicado: (2023)

Fibrous Papule of the Face, Similar to Tuberous Sclerosis Complex-Associated Angiofibroma, Shows Activation of the Mammalian Target of Rapamycin Pathway: Evidence for a Novel Therapeutic Strategy?
por: Chan, Jung-Yi Lisa, et al.
Publicado: (2014)

Nipple angiofibromas with loss of TSC2 are associated with tuberous sclerosis complex
por: Nathan, Neera, et al.
Publicado: (2015)

Dermoscopy of Facial Angiofibromas in Four Patients of Skin of Color with Tuberous Sclerosis Complex: A Case-Series
por: Jindal, Rashmi, et al.
Publicado: (2021)

Inhibition of the mechanistic target of rapamycin induces cell survival via MAPK in tuberous sclerosis complex
por: Lu, Yiyang, et al.
Publicado: (2020)

Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2011)

Early Sirolimus Gel Treatment May Diminish Angiofibromas and Prevent Angiofibroma Recurrence in Children With Tuberous Sclerosis Complex
por: Okanishi, Tohru, et al.
Publicado: (2020)

Atypical cutaneous presentation of tuberous sclerosis complex: Giant angiofibroma on the scalp
por: Freitas, Leonardo Furtado, et al.
Publicado: (2021)

Radiological Characteristics of Renal Lesions During Tuberous Sclerosis Complex: Impact of Mechanistic Target of Rapamycin Inhibitor Treatment
por: Pfirmann, Pierre, et al.
Publicado: (2022)

Characterization and management of facial angiofibroma related to tuberous sclerosis complex in the United States: retrospective analysis of the natural history database
por: Boggarapu, Sreedevi, et al.
Publicado: (2022)

Retraction: Mammalian target of rapamycin inhibitors for treatment in tuberous sclerosis
por: Kim, Won Seop
Publicado: (2013)

Bronchial angiofibroma in tuberous sclerosis complex: A case report and literature review
por: Teng, Peikun, et al.
Publicado: (2021)

Insulinoma and Tuberous Sclerosis: A Possible Mechanistic Target of Rapamycin (mTOR) Pathway Abnormality?
por: Kang, Michael Yoon, et al.
Publicado: (2017)

Topical Rapamycin Therapy to Alleviate the Cutaneous Manifestations of Tuberous Sclerosis Complex: A Double-Blind, Randomized, Controlled Trial to Evaluate the Safety and Efficacy of Topically Applied Rapamycin
por: Koenig, Mary Kay, et al.
Publicado: (2012)

Topical rapamycin inhibits tuberous sclerosis tumor growth in a nude mouse model
por: Rauktys, Aubrey, et al.
Publicado: (2008)

Efficacy and safety of mTOR inhibitors (rapamycin and its analogues) for tuberous sclerosis complex: a meta-analysis
por: Li, Min, et al.
Publicado: (2019)

Antiepileptic Effect and Safety Profile of Rapamycin in Pediatric Patients With Tuberous Sclerosis Complex
por: Sadowski, Krzysztof, et al.
Publicado: (2022)

The Efficacy and Safety of Rapamycin in Children with Tuberous Sclerosis: A Cross-sectional Study
por: TEHRANI, Fateme, et al.
Publicado: (2023)

Koenen's tumor and facial angiofibromas in a case of Birt-Hogg-Dubé syndrome: A cutaneous contribution to growing evidence of a relationship with tuberous sclerosis complex
por: DiCicco, Beau, et al.
Publicado: (2016)

Safety of inactivated COVID-19 vaccine in tuberous sclerosis complex patients with epilepsy treated with rapamycin
por: Lu, Qian, et al.
Publicado: (2022)

Reflectance confocal microscopy features of facial angiofibromas
por: Millán-Cayetano, José-Francisco, et al.
Publicado: (2017)

Cooperative benefit for the combination of rapamycin and imatinib in tuberous sclerosis complex neoplasia
por: Govindarajan, Baskaran, et al.
Publicado: (2012)

Rapamycin-Insensitive Up-Regulation of Adipocyte Phospholipase A2 in Tuberous Sclerosis and Lymphangioleiomyomatosis
por: Li, Chenggang, et al.
Publicado: (2014)

Efficacy and safety of a mammalian target of rapamycin inhibitor in pediatric patients with tuberous sclerosis complex: A systematic review and meta-analysis
por: YANG, GUANG, et al.
Publicado: (2015)

MicroRNA-21 is Induced by Rapamycin in a Model of Tuberous Sclerosis (TSC) and Lymphangioleiomyomatosis (LAM)
por: Trindade, Anil J., et al.
Publicado: (2013)

Rapamycin reverses impaired social interaction in mouse models of tuberous sclerosis complex
por: Sato, Atsushi, et al.
Publicado: (2012)

Assessing the effectiveness of rapamycin on angiomyolipoma in tuberous sclerosis: a two years trial
por: Cabrera-López, Cristina, et al.
Publicado: (2012)

Cannot write session to /tmp/vufind_sessions/sess_je07ibi9sf36rkompse7h0b37h